Bevacizumab

Bevacizumab, as a humanized vascular endothelial growth factor (VEGF) antibody, is a highly effective monoclonal antibody. Bevacizumab can be used for the research of cancer[1][2].

Research Areas >> Cancer

Signaling Pathways >> Others >> Others

Bevacizumab-loaded hydrogel results in significant tumor reduction. Bevacizumab is taken up by other organs, including the heart, lung, and spleen. Bevacizumab accumulates higher within tumors via Bevacizumab-loaded hydrogel administration from 14 days onward as compared to the solution formulation. Bevacizumab (I.v.) solution, a typical drug clearance profile is observed where the antibody is cleared from the circulatory system with a half-life of ~4~5 days. The Bevacizumab-loaded hydrogel and the weekly administration of Bevacizumab solution inhibits tumor growth/metastasis in the peritoneal cavity, while one-time i.v. injection of Bevacizumab solution does not provide any therapeutic effect, leading to extensive tumor metastasis[2].

[1]. Liu W, et al. Effect of Avastin on the migration and invasion of pterygium fibroblasts. Eye Sci. 2014;29(4):214-218.

[2]. Lee AL, et al. Injectable biodegradable hydrogels from vitamin D-functionalized polycarbonates for the delivery of avastin with enhanced therapeutic efficiency against metastatic colorectal cancer. Biomacromolecules. 2015;16(2):465-475.